Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use
- PMID: 30129508
- DOI: 10.1016/j.jnma.2017.12.007
Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use
Abstract
Background/purpose: Little is known about primary care physicians' (PCPs) beliefs about prostate cancer screening efficacy, evidence uncertainty, and their actual screening behaviors. We examined factors associated with PCP beliefs about screening efficacy and uncertainty and whether beliefs were associated with prostate specific-antigen (PSA) test use.
Methods: The 2008 National Survey of Primary Care Physicians' Practices Regarding Prostate Cancer Screening collected information on physicians' attitudes, beliefs, and practices related to prostate cancer and screening (n=1,256). Two factors were constructed that measured belief in certainty of evidence for PSA testing and belief in screening efficacy. These factors, along with PCP sociodemographic and practice-related factors, were used to examine associations with offering the PSA test.
Results: Most PCPs were male (70%), Caucasian (76%), under age 50 (56%), and practiced in communities with more than 50,000 residents (54%). In bivariate analysis, variables associated with PCP belief in evidence uncertainty included female gender, younger age, and lower patient volume. Variables associated with belief in screening efficacy included older age and general and family practice specialty. After adjustment, PCPs with high belief in evidence uncertainty were less likely (OR=0.19, 95% CI=0.06, 0.62) to offer PSA and more likely to practice shared decision making (OR=1.80, 95% CI=1.22-2.67). PCPs with high belief in screening efficacy were more likely (OR=2.99, 95% CI=1.15, 7.77) to offer PSA and less likely to practice shared decision making (OR=0.47, 95% CI=0.32-0.70).
Conclusion: Our data indicate that belief patterns about evidence uncertainty and the efficacy of using PSA may play a role in whether PCPs offer PSA.
Keywords: Primary care; Prostate cancer; Prostate-specific antigen; Screening.
Copyright © 2018 National Medical Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prostate cancer screening practices in a large, integrated health system: 2007-2014.BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26. BJU Int. 2017. PMID: 28139034 Free PMC article.
-
Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.Acta Oncol. 2013 Nov;52(8):1602-8. doi: 10.3109/0284186X.2012.762998. Epub 2013 Feb 19. Acta Oncol. 2013. PMID: 23421929 Clinical Trial.
-
Primary care physicians' use of an informed decision-making process for prostate cancer screening.Ann Fam Med. 2013 Jan-Feb;11(1):67-74. doi: 10.1370/afm.1445. Ann Fam Med. 2013. PMID: 23319508 Free PMC article.
-
Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393. Semin Urol Oncol. 2002. PMID: 11828353 Review.
-
Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.BMJ. 2018 Sep 5;362:k3581. doi: 10.1136/bmj.k3581. BMJ. 2018. PMID: 30185545 Free PMC article. No abstract available.
Cited by
-
General practitioners' reflections on using PSA for diagnosis of prostate cancer. A qualitative study.Scand J Prim Health Care. 2022 Mar;40(1):123-128. doi: 10.1080/02813432.2022.2057032. Epub 2022 Apr 12. Scand J Prim Health Care. 2022. PMID: 35412395 Free PMC article.
-
Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.Front Oncol. 2021 Jun 4;11:691197. doi: 10.3389/fonc.2021.691197. eCollection 2021. Front Oncol. 2021. PMID: 34150662 Free PMC article.
-
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16. Nat Rev Urol. 2022. PMID: 35974245 Review.
-
Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.BMC Cancer. 2021 Aug 23;21(1):948. doi: 10.1186/s12885-021-08646-2. BMC Cancer. 2021. PMID: 34425772 Free PMC article.
-
Shared decision-making before prostate cancer screening decisions.Nat Rev Urol. 2024 Jun;21(6):329-338. doi: 10.1038/s41585-023-00840-0. Epub 2024 Jan 2. Nat Rev Urol. 2024. PMID: 38168921 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous